HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sensa Class Action Complaint Gets Second Shot At Certification

This article was originally published in The Rose Sheet

Executive Summary

A federal judge denied certification without prejudice, allowing plaintiff's attorneys to file an amended complaint with arguments and evidence countering reasons for denying certification as a class. Two other complaints were resolved in settlements following FTC's settlement with Sensa Products and its parent firm in 2014 for $26.5m.

You may also be interested in...



Ad Firm Behind Bogus Weight Loss Claims Fined $2M: Health And Wellness Industry News

FTC and Maine would collect $2m under a settlement on complaint that Marketing Architects created ads for a weight loss supplement firm already targeted by FTC for false claims; Long Life Unlimited warned on claims; and UK catalog claims healing powers for meristem.

FTC Settles Big With Sensa, Other Weight-Loss Marketers

FTC settles with Sensa products and three other weight-loss product marketers, and launches its “gut check” voluntary media partnership program to prevent bogus claims. A firm cited in FTC’s 2011 investigation of human chorionic gonadotropin product ads also reached a settlement with the agency.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel